Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis inhibitors.

T R Tennant1, C W Rinker-Schaeffer, W M Stadler

  • 1Section of Hematology/Oncology, University of Chicago, 5841 South Maryland, MC2115, Chicago, IL 60637, USA.

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

Clinical pharmacology and therapeutics·2017
Same author

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.

Clinical pharmacology and therapeutics·2016
Same author

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2013
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Angiogenesis inhibitors combat tumor growth by targeting new blood vessel development. This review categorizes these drugs by mechanism and discusses clinical trial design for growth inhibition.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Research

Background:

  • Tumor growth is hypothesized to depend on neovascularization.
  • Angiogenesis inhibitors are a therapeutic strategy targeting this process.
  • These inhibitors are in clinical trials for various cancers.

Purpose of the Study:

  • To review current angiogenesis inhibitors.
  • To categorize inhibitors based on their mechanism of action.
  • To discuss challenges in clinical trial design for these agents.

Main Methods:

  • Categorization of angiogenesis inhibitors into five classes based on target activity.
  • Review of drug properties and specific agents within each class.
  • Discussion of clinical trial design considerations.

Related Experiment Videos

Main Results:

  • Angiogenesis inhibitors are classified into five groups: blocking matrix breakdown, inhibiting endothelial cells directly, blocking activators, inhibiting integrins/survival signaling, and unknown mechanisms.
  • Specific examples of agents within each category are presented.
  • Expected clinical effect is tumor growth inhibition, not shrinkage.

Conclusions:

  • Understanding the mechanisms of angiogenesis inhibitors is crucial for their development.
  • Clinical trial designs must account for the expected outcome of growth inhibition.
  • Further research is needed to optimize the use of these agents in cancer therapy.